Japan Grants Global First Nod For Brodalumab, For Psoriasis
This article was originally published in PharmAsia News
Executive Summary
Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibodies for the disorder in a new batch of approvals that also includes Praluent and Kyprolis.